The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...
StockStory.org on MSN
3 reasons LH is risky and 1 stock to buy instead
Labcorp currently trades at $265.08 per share and has shown little upside over the past six months, posting a middling return ...
Earlier this week, Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare ...
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results